Drug Labeling With Tiered Evidence Levels Eyed As Fix For Off-Label Promotion
This article was originally published in The Pink Sheet Daily
Executive Summary
Working group convened by Duke-Margolis Center for Health Policy lays out several policy proposals aimed at addressing current regulatory challenges with communication about unapproved uses of existing products.